Metadata of the chapter that will be visualized in Online
|
|
- Albert Lewis
- 5 years ago
- Views:
Transcription
1 Metadata of the chapter that will be visualized in Online Series Title Chapter Title Glaucomas: Neovascular Glaucoma Chapter SubTitle Copyright Year 2010 Copyright Holder Springer-Verlag Berlin Heidelberg Corresponding Author Family Name Wenick Particle Given Name Adam S Suffix Division Wilmer Eye Institute Organization Johns Hopkins Hospital Address 600 N Wolfe Street, Wilmer B20, , Baltimore, MD, USA awenick1@jhmi.edu Author Family Name Particle Given Name Suffix Division Organization Address Robin Alan L Wilmer Eye Institute Johns Hopkins Hospital 600 N Wolfe Street, Wilmer B20, , Baltimore, MD, USA Abstract The mainstays of medical treatment for neovascular glaucoma (NVG) are aqueous suppressants, topical steroids, and cycloplegics. Preliminary results suggest that antivascular endothelial growth factor (VEGF) therapy has a role in the treatment of NVG as a bridge to pan-retinal photocoagulation (PRP) and surgery. Prompt PRP or other relevant treatment of underlying disease is vital to the preservation of vision in NVG. PRP should ideally be performed 2 3 weeks prior to glaucoma surgery to allow for surgery in an uninflamed eye with regressed neovascularization (NV). Tube shunts are usually the preferred surgical technique in NVG, but trabeculectomy can be as effective in eyes with angle closure and regressed NV. Currently, cyclophotocoagulation is generally reserved for eyes with poor visual potential or which have failed other treatment modalities, but the low rates of phthisis with current approaches warrant its further consideration for the treatment of NVG in specific cases. Despite regression of NV from effective PRP or anti-vegf therapy, surgery is still required to control NVG if angle closure has developed. The most common cause of treatment failure in NVG is progression of underlying disease.
2 1 2 Glaucomas: Neovascular Glaucoma Adam S. Wenick and Alan L. Robin Core Messages The mainstays of medical treatment for neovascular glaucoma (NVG) are aqueous suppressants, topical steroids, and cycloplegics. Preliminary results suggest that antivascular endothelial growth factor (VEGF) therapy has a role in the treatment of NVG as a bridge to panretinal photocoagulation (PRP) and surgery. Prompt PRP or other relevant treatment of underlying disease is vital to the preservation of vision in NVG. PRP should ideally be performed 2 3 weeks prior to glaucoma surgery to allow for surgery in an uninflamed eye with regressed neovascularization (NV). Tube shunts are usually the preferred surgical tech nique in NVG, but trabeculectomy can be as effective in eyes with angle closure and regressed NV. Currently, cyclophotocoagulation is generally reserved for eyes with poor visual potential or which have failed other treatment modalities, but the low rates of phthisis with current approaches warrant its further consideration for the treatment of NVG in specific cases What Medications Can Be Used to Control Neovascular Glaucoma? Topical and oral medical therapies are the initial treatment of choice to lower intraocular pressure (IOP) and limit vision loss and pain secondary to neovascular glaucoma (NVG) IOP Lowering Agents Therapies aimed at decreasing aqueous production (beta-blockers, topical and systemic carbonic anhydrase inhibitors, and alpha adrenergics) have the soundest rationale for use in NVG. No study is available in the literature comparing effectiveness of these various medications in NVG, and they are often required in combination. If the IOP is markedly elevated, it would not be inappropriate to commence simultaneously with an alpha-agonist, topical nonselective beta blocker, and topical carbonic anhydrase inhibitor. The use of oral carbonic anhydrase inhibitors (acetazolamide) in place of or in combination with topical therapy (dorzolamide or brinzolamide) is often employed in the acute setting, and conflicting reports exist regarding their relative effectiveness. While Maus A. S. Wenick ( ) Wilmer Eye Institute, Johns Hopkins Hospital, 600 N Wolfe Street, Wilmer B20, Baltimore, MD , USA awenick1@jhmi.edu Despite regression of NV from effective PRP or anti-vegf therapy, surgery is still required to control NVG if angle closure has developed. The most common cause of treatment failure in NVG is progression of underlying disease J. A. Giaconi (eds.), Pearls of Glaucoma Management, DOI: / _49, Springer-Verlag Berlin Heidelberg 2009 Giaconi_49.indd Chap1 5/11/2009 1:32:47 PM
3 A. S. Wenick and A. L. Robin [1] found oral acetazolamide to be more effective in reducing aqueous production and IOP than 2% topical dorzolamide in normal subjects, Rosenberg [2] found no difference in their effectiveness and no additive benefit of using both agents in combination in subjects with primary open angle glaucoma or ocular hypertension. Neither study found the combination of oral and topical carbonic anhydrase inhibitors to be more effective than oral therapy alone. It should be noted that both studies were performed in eyes with relatively normal anterior segments. The absorption and penetration of topical agents in eyes with an altered cornea, an altered anterior segment, and aqueous humor have not been well studied previously. It is unclear how these results extrapolate to NVG, where IOPs tend to be significantly higher than those in the studies cited above. Close monitoring of electrolytes should be employed with the long-term use of oral carbonic anhydrase inhibitors in this patient population that tends to have a high prevalence of concomitant renal disease, especially if patients are also taking thiazide or loop diuretics. It should be remembered that approximately two-thirds of subjects who use oral agents long term are unable to tolerate them due to systemic adverse events. If the above therapies are ineffective, osmotic agents such as intravenous mannitol 1 2 g/kg can be used to further lower pressure in the acute setting for both the patient s comfort and to improve visualization of the angle. However, osmotics may have limited efficacy in NVG due to breakdown of the blood-vitreous barrier. Caution and close monitoring of serum electrolytes and renal function should be employed with these agents. There is no data available regarding the use of prostaglandin analogues in NVG. However their effectiveness is questionable, as the uveal outflow path may be covered with neovascular membrane [3, 4]. Additionally, the use of prostaglandins could theoretically increase inflammation in NVG. There is no role for the use of topically administered muscarinic agents, as closed angles or membranes covering the trabecular meshwork render them ineffective [3]. Not only is IOP not typically lowered by these agents, but they may cause increased inflammation and discomfort [4, 5] and worsen synechial angle closure [4] Anti-Inflammatory and Anti- Angiogenic Medications Frequent administration of topical corticosteroid medications are recommended to reduce inflammation that is inevitably present [3]. There is minimal data on the role of oral steroids for this purpose, and it must be remembered that oral steroids could have significant adverse effects in diabetic patients. Intravitreal corticosteroid injections have also been proposed as a useful adjunctor primary therapy in the treatment of NVG [6]. Jonas treated four eyes with NVG caused by central retinal vein occlusion (CRVO) or proliferative diabetic retinopathy (PDR) with injection of 20 mg of crystalline triamcinolone acetonide alone and found that all four eyes had a marked decrease in rubeosis iridis with lowering of mean IOP from 26.5 ± 12.1 to ± 11.3 mmhg. However one of these eyes with initial IOP of 40 mmhg demonstrated no decrease in IOP after injection [6]. The use of intravitreal steroids remains unproven and no large scale trials have yet confirmed these initial results. The use of oral, topical, periocular, or intraocular steroids is certainly indicated for the treatment of the underlying disease in NVG caused by uveitic processes. Antivascular endothelial growth factor (VEGF) therapy shows promise in the treatment of NVG and is discussed further below Cycloplegics/Mydriatics Topical atropine sulfate 1% may be used for symptomatic relief of pain in NVG. It may also have some effect in lessening inflammation [7] and possibly in increasing aqueous outflow through the uveoscleral route, if this pathway is not blocked by fibrovascular membranes [4]. IOP lowering alone may decrease ischemia and therefore decrease the stimulus for neovascularization (NV) [8] ; but prompt medical or laser treatment of the underlying disorder is critical to prevent formation of peripheral anterior synechiae (PAS) and angle closure. Once extensive PAS have formed, surgical treatment is usually required to control IOP, despite regression of NV, as topical agents are rarely sufficiently effective once PAS have formed Giaconi_49.indd Chap2 5/11/2009 1:32:47 PM
4 49 Glaucomas: Neovascular Glaucoma Summary for the Clinician Aqueous suppressants, beta-blockers, carbonic anhydrase inhibitors (topical and oral), and alpha adrenergics are the mainstay of treatment for the lowering of IOP in NVG. Oral acetazolamide and intravenous mannitol may be used with caution in the patient population due to a high prevalence of concomitant renal disease. Intense topical corticosteroids are recommended to quell the prominent inflammatory response in NVG. Topical atropine is also recommended for symptomatic relief and may decrease IOP and inflammation in NVG. Failure of medical therapy alone is the rule in advanced NVG What Is the Surgical Treatment of Choice for Neovascular Glaucoma? Should Everyone Always Get a Tube Shunt to Control IOP, i.e., Can a Trabeculectomy Be Useful? The three modalities most often employed when medical treatment fails to control IOP in NVG are tube shunts, trabeculectomy, and cycloablation. There is no role for laser trabeculoplasty in these highly abnormal angles. Almost 30 years ago, Simmons attempted to actually coagulate the angle s vessels, but produced vascular spasm and minimal long-term coagulation [9, 10]. Understanding the pathogenesis and disease course of NVG is vital to understanding the surgical choices and reasons for surgical failures. In the initial stages of NVG, fibrovascular tissue grows over the trabecular meshwork leading to decreased aqueous outflow and increased IOP. Next, myofibroblasts present in the neovascular tissue proliferate and contract, leading to progressive permanent angle closure and progressive increase in IOP. Corneal endothelial proliferation can also extend over the angle [11]. When deciding upon the best surgical option for a patient who has failed medical therapy and when analyzing the surgical literature, it is important to keep the above in mind and note that NVG is not a homogenous disease. Surgical failure in NVG is usually defined as an inability to control IOP, as well as the development of phthisis and/or loss of light perception, regardless of the specific etiology of the latter. While phthisis and loss of light perception can occur from glaucomatous damage due to high IOP or as a complication of glaucoma surgery, progression of underlying ischemic disease, rather than failure to control IOP, is the most common cause of failure of surgeries for NVG [12]. It is therefore important to interpret study results in the context of the natural history of the underlying disease. The ideal surgical treatment is influenced by the underlying disorder as well as the clinical characteristics of each patient i.e., IOP, presence of active vs. regressed NV, prior laser or VEGF therapy, prior intraocular surgical therapies, degree of inflammation, degree of angle closure, presence of hazy ocular media, and visual potential. Outcomes tend to be better in PDR compared to CRVOs [13], and ocular ischemic syndrome has the worst prognosis [3]. A majority of the literature concerning the surgical treatment of NVG consists of retrospective noncomparative case series [4]. Few comparative series and no prospective comparative studies or randomized trials exist in the literature (Tables 49.1 and 49.2 ). Comparing techniques in these different series is impossible due to different measures of successful outcome, differing and insufficient follow up times, and different baseline patient characteristics, including differences in etiology of NVG, baseline visual function, degree of NVA and PAS, and percentage of patients who have undergone pan-retinal photocoagulation (PRP). In many of these reports, all of these details are not even available. Early studies with cyclocryoablation reported a large percentage of patients with vision loss and phthisis [35], relegating the use of cyclocryoablation and cyclophotocoagulation only to eyes with limited visual potential [4]. These early studies did not employ graduated cycloablation, which results in better outcomes [36, 37] and which some advocate as primary therapy in some cases even when there is good visual potential [3]. The bias towards using cycloablation only in eyes with poor visual potential, combined with the retrospective nature of studies in the literature has led to a reinforcement of the belief that cycloablation should only be used when visual prognosis is poor. Eid found better outcomes with tube shunts compared to Giaconi_49.indd Chap3 5/11/2009 1:32:47 PM
5 A. S. Wenick and A. L. Robin AQ Sidoti [8] cyclophotocoagulation in a retrospective study in which patients were matched in terms of underlying disease. However, in the cyclophotocoagulation group only 4.2% of patients had a visual acuity better than count fingers, while in the tube shunt group 41.7% of patients had vision better than count fingers. Additionally, a larger proportion of patients in the cyclophotocoagulation group had 360 of angle closure [17], bringing the conclusions of this report into question. Currently, most glaucoma specialists recommend cyclophotocoagulation only in eyes with poor visual prognosis or when other methods have failed to control IOP. However, further studies are needed to evaluate the role of graduated cyclophotocoagulation in NVG, as some promising results have been published [37]. A study by Tsai reporting poor long-term Eid [17] a Minkler [18] Lloyd [19] Downes [20] Freedman [21] Ancker [22] results of trabeculectomy with 5-FU in NVG 5 year survival rate of filtering surgery with 5-FU was only 28% is often cited as a rational for using tube shunts rather then trabeculectomy for NVG [11]. However these results are similar to long-term results with tube shunts (Tables 49.1 and 49.2 ) [13, 14]. The use of mitomycin C (MMC) may give superior results to 5-FU, though one small study found no difference between the two antimetabolites in NVG [38]. As mentioned above, failure of glaucoma surgery in NVG is most commonly caused by progression of underlying disease, and poor outcomes at 5 yearslikely represent this phenomenon rather than problems intrinsic to any one technique. In uninflammed NVG eyes treated with previous PRP, NVG becomes similar to uncomplicated angle closure and good results can be expected with Faghihi [23] Chalam [24] a Krupin Krupin Baerveldt Tube shunt b Molteno Molteno Molteno Molteno Molteno PPV + Ahmed PPV + Baerveldt 54(60) 38(38) 27(27) 92(92) 40(40) 79(79) 36(36) 24(24) 15(15) 18(18) 50(50) 18(18) 36(36) 17(18) 18(18) Table 49.1 Studies of NVG and tube shunt surgery Study Mermoud Yalvac Yalvac Susanna Krupin Krupin [13] [14] a [14] a [15] [5] [16] Technique Molteno Ahmed Molteno Ahmed + MMC Number of patients (eyes) IOP Mean age NR Mean followup (months) Percentage of 62.1, 52.9, 63.2, 43.1, 30.8, 56.2, 37.0, 29.6, d 79, success 10.3 c 43.2, 37.8, 25.2 c 29.6, 29.6, 29.6 c Criteria IOP IOP IOP IOP IOP IOP IOP IOP < 22e IOP IOP IOP <20 g IOP for < 22 e 6 21 e 6 21 e 5 21 f < 25 e < 25 e 6 21 e 6 25 e 6 21 e < 26 e < 22 e 5 21 e 6 21 success PRP/cryo NR NR NR NR NR NR (%) DR NR NR RVO NR NR Other NR NR NR data not reported acomparative study b Molteno, Ahmed, Baerveldt, or Schocket c Kaplan-Meier life-table success at 1, 2, 3, 4, 5 years d Kaplan-Meier life-table success at 12 and 18 months e ± IOP lowering drops, no phthisis, no further surgery f With at least 30% reduction in IOP, ± IOP lowering drops, no phthisis gwithout medications Giaconi_49.indd Chap4 5/11/2009 1:32:47 PM
6 49 Glaucomas: Neovascular Glaucoma Table 49.2 Studies of NVG and filtering surgery Study Allen [7] Technique Trab/ PLS Number of patients (eyes) Euswas [25] Mandal [26] Kiuchi [27] Herschler [28] Elgin [12] TMMC TMMC TMMC Trab TMMC + iris cauterization Tsai [11] trabeculectomy [29, 30]. That being said, younger eyes [11] and eyes with prior vitrectomy [27] tend to fare worse with trabeculectomy. The ability of anti-vegf agents to induce rapid regression of NV of the angle and iris (discussed below) may lead to an expanded role for trabeculectomy in NVG. As noted above, for many glaucoma specialists, tube shunts have become the treatment of choice for NVG. While trabeculectomy is a viable option in quiet eyes with regressed NV, tubes shunts seem to be a better choice in inflamed eyes where failure rates of Flanagan [29] Clearkin [30] Lee [31] Fernandez- Vigo [32] Kiuchi [33] PG trabeculectomy are highest. While many advocate the use of one type of tube over others, the results with different devices are roughly equivalent [39] (see Table 49.1 ). As with trabeculectomy, tube shunt results are worse when used for NVG than for other types of glaucoma [40]. It is recommended that tube shunts be placed as far posterior as possible, i.e., at the pars plana in eyes that have undergone vitrectomy and in the sulcus in pseudophakic eyes. This will help to avoid corneal decompensation and blockage of tubes from neovascular membranes. Kiuchi [33] PC Kono [34] Trab/ Trab Trab Modified Trab PPV+ PPV + PLS + Trab filtering 5-FU 22(24) 21(23) 14(15) 35(35) 13(13) 72(72) 34(34) 6(6) 6(6) 5(5) 23(26) 9(9) 16(16) 18(21) Mean age Mean followup (months) NR Percentage , , , 27c 55.6, 81.3, 81.3, 90.5 of success 61.8, 61.8 a 67, 61, 41, 28 b 18.5? a 81.3 a Criteria IOP IOP IOP IOP IOP IOP IOP useful IOP IOP IOP IOP IOP IOP for < 25 d < 22 d < 22 e < 22 d 6 26 f < 23 d < 22 d vision < 22 d 4 20 d < 23 f < 22 d < 22 d 5 21 d success PRP/cryo g NR NR (%) DR RVO Other PLS posterior lip sclerotomy; TMMC trabeculectomy with mitomycin C; NR data not reported. PG proliferative group-vitreous hemorrhage, fibrovascular membrane, and/or retinal detachment. PC NVG but no vitreous hemorrhage, fibrovascular membrane, or retinal detachment a Kaplan-Meier life-table success at 12, 24 and 36 months b Kaplan-Meier life-table success at 1, 2, 3, 4, 5 years c Percentage success at 12 and 24 months d ± IOP lowering drops, no phthisis, no further surgery ewithout medications f ± IOP lowering drops, allowed additional surgery gafter filtering surgery Giaconi_49.indd Chap5 5/11/2009 1:32:48 PM
7 A. S. Wenick and A. L. Robin Summary for the Clinician Comparison of surgical techniques to treat NVG is severely limited due to a dearth of comparative and prospective studies as well as differing outcome measures and baseline patient characteristics in various studies. Though tube shunts are considered by many to be the surgical treatment of choice in NVG, trabeculectomy and tube shunts are likely equivalent in quiet eyes with regressed NV. Tubes shunts or cycloablation are more likely to be effective in inflamed eyes with active NV. Cycloablation is most often employed only in eyes with poor visual potential, but graduated cyclophotocoagulation may have a primary role in treatment of eyes with good visual potential, and its use should be further investigated. Over the long term, all surgical techniques share poor outcomes in NVG in large parts due to progression of underlying disease How Should PRP and Glaucoma Surgery Be Timed? Determining the timing of PRP with relation to surgery must take into account the characteristics of the individual patient s disease. Factors such as media opacities and significantly elevated IOP, despite maximal medical therapy, may lead to glaucoma surgery sooner than would otherwise be desired. Ideally if given the luxury, PRP should be performed 2 3 weeks prior to filtering or tube implant surgery. This allows adequate time for the beneficial effects of PRP to take effect, including regression of iris and angle NV and a decrease in ocular inflammation, reducing the rates of intraoperative complications (hyphema) and early complications due to a prominent inflammatory response (such as bleb failure) [7, 12, 26, 29]. Eyes with previously healthy optic nerves likely can tolerate IOP in the mid 30s during this period after PRP. Already severely damaged optic nerves, from asymptomatic IOP elevation or from POAG for instance, may not be able to tolerate these same IOPs for 2 3 weeks without further significant optic neuropathy [7]. Inability to control IOP to at least these levels (the mid 30s) is an indication for prompt glaucoma surgery. The clinician must also keep in mind that PRP can lead to a further increase in IOP [3], necessitating close follow-up in the interim period. Recently Euswas and Warrasak published promising results in which PRP was delayed until at least 1 week after trabeculectomy with mitomycin-c because of hazy ocular media [25]. In their consecutive series of 21 patients and 23 eyes, they had a qualified success rate of 91.3% with follow-up of months (mean 29 ± 11.3) [25]. Finally early data from the use of anti-vegf agents indicate that their use may obviate the need to wait for PRP to take effect prior to glaucoma surgery, as discussed below. Summary for the Clinician PRP should if possible, precede glaucoma surgery by 2 3 weeks to allow for regression of NV prior to surgical intervention, but this is often not possible due to hazy ocular media or significantly elevated IOP despite maximal medical management Is Bevacizumab Useful in Neovascular Glaucoma? What Kind of Results and Time-Course Can I Expect from Its Use? For NV of the Iris, Should It Be Injected into the Anterior Chamber or Vitreal Cavity? Multiple case reports /case series have been published showing promising results with the use of both intravitreal and intracameral bevacizumab (Figs and 49.2 ) in cases of iris NV and NVG secondary to PDR, CRVO, ocular ischemic syndrome, and radiation retinopathy [41 52]. In the largest of these studies, Avery studied the effects of intravitreal bevacizumab (6.25 m g 1.25 mg) on 45 eyes of 32 patients with iris or retinal NV from PDR. Of the 11 eyes with iris NV, 9 eyes (82%) showed complete regression of NV, while the remaining 2 eyes showed only partial regression Giaconi_49.indd Chap6 5/11/2009 1:32:48 PM
8 49 Glaucomas: Neovascular Glaucoma Table 49.3 Doses used for bevacizumab in neovascular glaucoma Anterior chamber dose 1.25 mg/0.05 ml 1.00 mg/ 0.04 ml Posterior chamber dose 0.5 mg/0.2 ml Fig Bevacizumab prepared for intravitreal injection by the chemotherapy pharmacist Fig A patient receiving intravitreal bevacizumab for neovascularization of the angle and iris due to proliferative diabetic retinopathy Leakage on iris flourescein angiogram was noted to diminish in as little as 24 h. Recurrent leakage was seen as early as 2 weeks following injection and effects lasted up to the maximum follow-up time of 11 weeks in some eyes. Effects on IOP were not reported in this paper, nor were the number of eyes with NVG [43]. The largest consecutive case series looking at the use of bevacizumab specifically in NVG was reported by Iliev (retinal vein occlusions) [47] and Gheith (PDR and CRVOs) [45] (Table 49.3 ). Both reviews included six consecutive patients who were given injections of 1.25 mg of intravitreal bevacizumab. In the study by Iliev, all cases showed marked regression of anterior segment NV, relief of symptoms within 48 h, while substantial lowering of IOP occurred in 3 of 6 eyes. Adjuvant cyclophotocoagulation was performed in the remaining 3, and subsequent PRP was performed in all eyes. The follow-up period was 4 16 weeks, and all patients had stable or improved vision, regression of angle and iris NV, and resolution of pain and anterior chamber inflammation at the end of follow-up [47]. In the study by Gheith with a follow up period of 3 19 months (average 9.7 months), all cases showed complete regression of iris and angle NV with lowering of IOP at 1 week. Subsequent PRP was done at this time. Iris NV recurred in one case at 3 months and in a second case at 5 months. IOP was controlled with topical agents in cases without PAS, but subsequent glaucoma surgery (tube shunt or TMMC) was required to control IOP in patients with PAS [45]. Similar results were reported in the only published study in which intracameral bevacizumab was used [46]. These findings suggest that intracameral bevacizumab is most useful in NVG when given before PAS form and cause permanent damage to the aqueous outflow pathways.in all studies, no adverse effects were reported. As discussed by the authors cited above, bevacizumab seems to be a promising adjunct to PRP in the treatment of NVG. The duration of action is unknown and it is likely that repeat injections would be required to control NVG when used as a sole agent. The transient effects of current anti-vegf treatments make their use most promising as a temporizing measure until PRP results can take effect, or prior to glaucoma surgery. When using intravitreal or intracameral bevacizumab, AQ2 AQ3 Giaconi_49.indd Chap7 5/11/2009 1:32:48 PM
9 A. S. Wenick and A. L. Robin it is important to keep in mind the short term elevation in IOP that may occur after injection [53]. The finding that at least moderate amounts of IOP rise are to be expected immediately after injection [53] may necessitate paracentesis in eyes with already markedly elevated IOP from NVG prior to any intraocular injection. However one should keep in mind that hemorrhagic complications (including hyphema and suprachoroidal hemrrhage) may occur with acute reduction of IOP by paracentesis. Additionally, one should be aware that long term elevation in IOP has been reported as an uncommon side effect after injection of intravitreal bevacizumab [53, 54]. Summary for the Clinician Cursory studies of the use of intravitreal bevacizumab in NVG have shown promising results, but better controlled studies with longer follow up are needed to establish its role in the treatment of NVG. Results in terms of regression of NV, decrease in inflammation, and lowering of IOP can be expected in as little as 48 h after injection of bevacizumab. Despite the dramatic effects that have been reported with intraocular bevacizumab in NVG, surgery is still required if significant angle closure has developed. Currently, given its rapid onset of efficacy but short duration of action, intraocular anti- VEGF therapy is most useful as a bridge or adjunct to PRP and glaucoma surgery rather than a definitive treatment for NVG. References 1. Maus TL, Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol 1997 ;115(1): Rosenberg LF, Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation. Ophthalmology 1998 ;105(1): 88 92; discussion Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res 2007 ;26(5): Sivak-Callcott JA, Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 2001 ;108(10): ; quiz 1777, Krupin T, Filtering valve implant surgery for eyes wtih neovascular glaucoma. Am J Ophthalmol 1980 ;89(3): Jonas JB, Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J Glaucoma 2001 ;10(4): Allen RC, Filtration surgery in the treatment of neovascular glaucoma. Ophthalmology 1982 ;89(10): Sidoti PA, Experience with the Baerveldt glaucoma implant in treating neovascular glaucoma. Ophthalmology 1995 ;102(7): Simmons RJ, Deppermann SR, Dueker DK. The role of gonio-photocoagulation in neovascularization of the anterior chamber angle. Ophthalmology 1980 ;87(1): Simmons RJ, Goniophotocoagulation for neovascular glaucoma. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 1977 ;83(1): Tsai JC, 5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study. Ophthalmology 1995 ;102(6): ; discussion Elgin U, Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma. J Glaucoma 2006 ;15(5): Mermoud A, Molteno tube implantation for neovascular glaucoma. Long-term results and factors influencing the outcome. Ophthalmology 1993 ;100(6): Yalvac IS, Long-term results of Ahmed glaucoma valve and Molteno implant in neovascular glaucoma. Eye 2007 ; 21 (1): Susanna R Jr. Partial Tenon s capsule resection with adjunctive mitomycin C in Ahmed glaucoma valve implant surgery. Br J Ophthalmol 2003 ;87(8): Krupin T, Long-term results of valve implants in filtering surgery for eyes with neovascular glaucoma. Am J Ophthalmol 1983 ;95(6): Eid TE, Tube-shunt surgery versus neodymium:yag cyclophotocoagulation in the management of neovascular glaucoma. Ophthalmology 1997 ;104(10): Minckler DS, Clinical experience with the single-plate Molteno implant in complicated glaucomas. Ophthalmology 1988 ;95(9): Lloyd MA, Clinical experience with the single-plate Molteno implant in complicated glaucomas. Update of a pilot study. Ophthalmology 1992 ;99(5): Downes RN, The Molteno implant in intractable glaucoma. Eye 1988 ;2(Pt 3) : Freedman J, Rubin B. Molteno implants as a treatment for refractory glaucoma in black patients. Arch Ophthalmol 1991 ;109(10): Ancker E, Molteno AC. Molteno drainage implant for neovascular glaucoma. Trans Ophthalmol Soc U K 1982 ;102(Pt 1) : Faghihi H, Pars plana Ahmed valve implant and vitrectomy in the management of neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2007 ;38(4): Chalam KV, Pars plana modified Baerveldt implant versus neodymium:yag cyclophotocoagulation in the Giaconi_49.indd Chap8 5/11/2009 1:32:50 PM
10 49 Glaucomas: Neovascular Glaucoma management of neovascular glaucoma. Ophthalmic Surg Lasers 2002 ;33 (5) : Euswas A, Warrasak S. Long-term results of early trabeculectomy with mitomycin-c and subsequent posterior segment intervention in the treatment of neovascular glaucoma with hazy ocular media. J Med Assoc Thai 2005 ;88 (11) : Mandal AK, Mitomycin-C-augmented trabeculectomy for neovascular glaucoma. A preliminary report. Indian J Ophthalmol 2002 ;50 (4) : Kiuchi Y, Trabeculectomy with mitomycin C for treatment of neovascular glaucoma in diabetic patients. Ophthalmologica 2006 ;220 (6) : Herschler J, Agness D. A modified filtering operation for neovascular glaucoma. Arch Ophthalmol 1979 ;97 (12) : Flanagan DW, Blach RK. Place of panretinal photocoagulation and trabeculectomy in the management of neovascular glaucoma. Br J Ophthalmol 1983 ;67 (8) : Clearkin LG. Recent experience in the management of neovascular glaucoma by pan-retinal photocoagulation and trabeculectomy. Eye 1987 ;1 (Pt 3) : Lee PF, Shihab ZM, Fu YA. Modified trabeculectomy: A new procedure for neovascular glaucoma. Ophthalmic Surg 1980 ;11 (3) : Fernandez-Vigo J, Treatment of diabetic neovascular glaucoma by panretinal ablation and trabeculectomy. Acta Ophthalmol (Copenh) 1988 ;66 (6) : Kiuchi Y, Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol 2006 ;244 (12) : Kono T, Long-term results of pars plana vitrectomy combined with filtering surgery for neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2005 ;36 (3) : Krupin T, Mitchell KB, Becker B. Cyclocryotherapy in neovascular glaucoma. Am J Ophthalmol 1978 ;86 (1) : Chang SH, Contact diode laser transscleral cyclophotocoagulation for refractory glaucoma: Comparison of two treatment protocols. Can J Ophthalmol 2004 ;39 (5) : Delgado MF, Long-term results of noncontact neodymium:yttrium-aluminum-garnet cyclophotocoagulation in neovascular glaucoma. Ophthalmology 2003 ; 110 (5) : Sisto D, The role of antimetabolites in filtration surgery for neovascular glaucoma: Intermediate-term follow-up. Acta Ophthalmol Scand 2007 ;85 (3) : Hong CH, Glaucoma drainage devices: A systematic literature review and current controversies. Surv Ophthalmol 2005 ;50 (1) : Das JC, The Ahmed glaucoma valve in refractory glaucoma: Experiences in Indian eyes. Eye 2005 ;19 (2) : Oshima Y, Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006 ;142 (1) : Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006 ;26 (3) : Avery RL, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006 ;113 (10) : 1695.e Chilov MN, Grigg JR, Playfair TJ. Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Experiment Ophthalmol 2007 ;35 (5) : Gheith ME, Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 2007 ;23 (5) : Grisanti S, Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006 ;142 (1) : Iliev ME, Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006 ; 142 (6) : Kelkar AS, et al. The use of intravitreal bevacizumab in neovascular glaucoma: A case report. Bull Soc Belge Ophtalmol 2007 ; (303) : Mason JO III, Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 2006 ;26 (7) : Silva Paula J, Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand 2006 ;84 (4) : Vatavuk Z, Bencic G, Mandic Z. Intravitreal bevacizumab for neovascular glaucoma following central retinal artery occlusion. Eur J Ophthalmol 2007 ;17 (2) : Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma 2007 ;16 (5) : Hollands H, Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007 ;42 (6) : Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: An unreported complication. Eye 2007 ;21 (12) : Author Queries [AQ1] Per style footnotes has to be designated with alphabets. Please check whether the footnotes e, f are appropriate. [AQ2] Please check whether the insertion of the table 49.3 citation here is appropriate. [AQ3] Please check the sentence, These pathways for meaning and completeness. Giaconi_49.indd Chap9 5/11/2009 1:32:50 PM
MANAGEMENT OF NEOVASCULAR GLAUCOMA
MSO EXPRESS: ISSUE 3 MANAGEMENT OF NEOVASCULAR GLAUCOMA Associate Professor Dr. Norlina Mohd Ramli, Dr. Ng Ker Hsin Associate Professor Dr. Norlina Mohd Ramli MBBS (UK) MRCOphth (UK) MS Ophthal (Mal) Fellowship
More informationNIH Public Access Author Manuscript Int Ophthalmol Clin. Author manuscript; available in PMC 2012 July 1.
NIH Public Access Author Manuscript Published in final edited form as: Int Ophthalmol Clin. 2011 ; 51(3): 27 36. doi:10.1097/iio.0b013e31821e5960. Medical and Surgical Treatment of Neovascular Glaucoma
More informationWGA. The Global Glaucoma Network
The Global Glaucoma Network Fort Lauderdale April 30, 2005 Indications for Surgery 1. The decision for surgery should consider the risk/benefit ratio. Note: Although a lower IOP is generally considered
More informationEfficacy and Safety of Intracameral Bevacizumab for Treatment of Neovascular Glaucoma
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2017;31(6):538-547 https://doi.org/10.3341/kjo.2017.0017 Original Article Efficacy and Safety of Intracameral Bevacizumab for Treatment of Neovascular
More informationClinical Study Results of Combined Cyclectomy/Trabeculectomy Procedure Compared with Ahmed Glaucoma Valve Implant in Neovascular Glaucoma Cases
International Scholarly Research Network ISRN Ophthalmology Volume 2011, Article ID 680827, 6 pages doi:10.5402/2011/680827 Clinical Study Results of Combined Cyclectomy/Trabeculectomy Procedure Compared
More informationObjectives. Tubes, Ties and Videotape: Financial Disclosure. Five Year TVT Results IOP Similar
Tubes, Ties and Videotape: Surgical Video of Glaucoma Implants and Financial Disclosure I have no financial interests or relationships to disclose. Herbert P. Fechter MD, PE Eye Physicians and Surgeons
More informationThe effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma
European Journal of Ophthalmology / Vol. 19 no. 3, 2009 / pp. 435-441 The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma VINEY GUPTA
More informationIntravitreal ranibizumab for neovascular glaucoma: an interventional case series
ORIGINAL ARTICLE Intravitreal ranibizumab for neovascular glaucoma: an interventional case series Ian Y. H. Wong, 1 M.Med (Singapore), MRCSEd, FHKAM (Ophthalmology), Simon C. Y. Koo, 2 FCOphthHK, FHKAM
More informationResearch Article Prognostic Factor Analysis of Intraocular Pressure with Neovascular Glaucoma
Journal of Ophthalmology Volume 216, Article ID 125895, 9 pages http://dx.doi.org/1.1155/216/125895 Research Article Prognostic Factor Analysis of Intraocular Pressure with Neovascular Glaucoma Satoko
More informationNeovascular glaucoma (NVG) is the end result of. Clinical Experience in the Management of Neovascular Glaucoma. Original Article METHODS
Original Article J Chin Med Assoc 2004;67:131-135 Tung-Mei Kuang Catherine Jui-Ling Liu Ching-Kuang Chou Wen-Ming Hsu Department of Ophthalmology, Taipei Veterans General Hospital and National Yang-Ming
More informationSILICONE OIL INJECTION INDUCED GLAUCOMA: INCIDENCE AND MANAGEMENT
SILICONE OIL INJECTION INDUCED GLAUCOMA: INCIDENCE AND MANAGEMENT Ahmad Elsayed Hudieb Department of Ophthalmology Faculty of Medicine, Al- Azhar University ABSTRACT Purpose: Intravitreal silicone oil
More informationA Prospective Study to Evaluate Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma
Ophthalmol Ther (2015) 4:33 41 DOI 10.1007/s40123-015-0033-3 ORIGINAL RESEARCH A Prospective Study to Evaluate Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma
More informationAqueous Shunts for the Treatment of Glaucoma
TITLE: Aqueous Shunts for the Treatment of Glaucoma AUTHOR: Jeffrey A. Tice, MD Assistant Professor of Medicine Division of General Internal Medicine Department of Medicine University of California San
More informationStudy of the Effect of Injection Bevacizumab through Various Routes in Neovascular Glaucoma
JOCGP Original Article Study of the Effect of Injection Bevacizumab through Various 10.5005/jp-journals-10008-1200 Routes in Neovascular Glaucoma Study of the Effect of Injection Bevacizumab through Various
More informationFive-year Treatment Outcomes in the Ahmed Baerveldt Comparison (ABC)Study
Five-year Treatment Outcomes in the Ahmed Baerveldt Comparison (ABC)Study Donald L Budenz, MD, MPH; Keith Barton, MD; Steven J Gedde, MD; William J Feuer, MS; Joyce Schiffman, MS; Vital P Costa, MD; David
More informationClinical Study Effect of Preoperative Intravitreal Bevacizumab on the Surgical Outcome of Neovascular Glaucoma at Different Stages
Hindawi Ophthalmology Volume 2017, Article ID 7672485, 7 pages https://doi.org/10.1155/2017/7672485 Clinical Study Effect of Preoperative Intravitreal Bevacizumab on the Surgical Outcome of Neovascular
More informationA. Incorrect! Acetazolamide is a carbonic anhydrase inhibitor given orally or by intravenous injection.
Pharmacology - Problem Drill 20: Drugs that Treat Glaucoma Question No. 1 of 10 1. is a topical carbonic anhydrase inhibitor. Question #01 (A) Acetazolamide (B) Clonidine (C) Dorzolamide (D) Apraclonidine
More informationReview of the Ahmed versus Baerveldt study 5-year treatment outcomes
Perspective Page 1 of 5 Review of the Ahmed versus Baerveldt study 5-year treatment outcomes Victor Koh 1,2, Cecilia Maria Aquino 1, Paul Chew 1,2 1 Department of Ophthalmology, National University Hospital,
More informationmeasure of your overall performance. An isolated glucose test is helpful to let you know what your sugar level is at one moment, but it doesn t tell you whether or not your diabetes is under adequate control
More informationVI.2.2 Summary of treatment benefits
EU-Risk Management Plan for Bimatoprost V01 aetiology), both OAG and ACG can be secondary conditions. Secondary glaucoma refers to any case in which another disorder (e.g. injury, inflammation, vascular
More informationLandmark Tube Trials
SECTION EDITOR: BARBARA SMIT, MD, PhD Landmark Tube Trials A review of key findings from recent multicenter randomized clinical trials involving tube shunts. BY AMBIKA HOGUET, MD, AND STEVEN J. GEDDE,
More informationNeovascular Glaucoma
Ophthalmic Deliberations ISSN 0972-0200 Neovascular Glaucoma Sonal Dangda, Harsh Kumar, Kirti Singh, Tanuj Dada, Suneeta Dubey, Sirisha Senthil, Arun Narayanaswamy, Avnindra Gupta Harsh Kumar MD, DNB Senior
More informationIntravitreal Bevacizumab (IVB) In The Management of Recalcitrant Neovascular Glaucoma (NVG)
March 2008 Sonia Rani John et al. - IVB in NVG 33 ORIGINAL ARTICLE Intravitreal Bevacizumab (IVB) In The Management of Recalcitrant Neovascular Glaucoma (NVG) Dr. Sonia Rani John DNB, Dr. Meena Chakrabarti
More informationOCCLUSIVE VASCULAR DISORDERS OF THE RETINA
OCCLUSIVE VASCULAR DISORDERS OF THE RETINA Learning outcomes By the end of this lecture the students would be able to Classify occlusive vascular disorders (OVD) of the retina. Correlate the clinical features
More informationTRABECULECTOMY THE BEST AND WORST CANDIDATES
TRABECULECTOMY THE BEST AND WORST CANDIDATES MICHAEL F. OATS, MD OPHTHALMIC CONSULTANTS OF BOSTON ASCRS 2014 FINANCIAL DISCLOSURES None TRABECULECTOMY Performed for over 100 years Most commonly performed
More informationGlaucoma. How is Glaucoma Diagnosed? Glaucoma Testing
Glaucoma How is Glaucoma Diagnosed? Glaucoma Testing There is no single test for glaucoma. The diagnosis is made by evaluating the patient from a number of perspectives, using specialized instruments.
More informationLan Liu 1, Yongfeng Xu 2, Zhu Huang 1 and Xiaoyu Wang 1*
Liu et al. BMC Ophthalmology (216) 16:65 DOI 1.1186/s12886-16-248-7 RESEARCH ARTICLE Open Access Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of
More informationConcentration of Vascular Endothelial Growth Factor After Intracameral Bevacizumab Injection in Eyes With Neovascular Glaucoma
접수번호 : 2008-093 Korean Journal of Ophthalmology 2009;23:188-192 ISSN : 1011-8942 DOI : 10.3341/kjo.2009.23.3.188 Concentration of Vascular Endothelial Growth Factor After Intracameral Bevacizumab Injection
More informationIncidence and Clinical Features of Neovascularization of the Iris following Acute Central Retinal Artery Occlusion
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2016;30(5):352-359 http://dx.doi.org/10.3341/kjo.2016.30.5.352 Original Article Incidence and Clinical Features of Neovascularization of the Iris following
More informationThe Anterior Segment & Glaucoma Visual Recognition & Interpretation of Clinical Signs
The Anterior Segment & Glaucoma Visual Recognition & Interpretation of Clinical Signs Quiz created by Jane Macnaughton MCOptom & Peter Chapman BSc MCOptom FBDO CET Accreditation C19095 2 CET Points (General)
More informationPreliminary report on effect of retinal panphotocoagulation on rubeosis iridis and
British Journal of Ophthalmology, 1977, 61, 278-284 Preliminary report on effect of retinal panphotocoagulation on rubeosis iridis and neovascular glaucoma LEILA LAATIKAINEN From Moorfields Eye Hospital,
More informationVascular Disease Ocular Manifestations of Systemic Hypertension
Vascular Disease Ocular Manifestations of Systemic Hypertension Maynard L. Pohl, OD, FAAO Pacific Cataract & Laser Institute 10500 NE 8 th Street, Suite 1650 Bellevue, WA 98004 USA 425-462-7664 Cerebrovascular
More informationBevacizumab (Avastin ) for neovascular glaucoma secondary to ischaemic central retinal vein occlusion
Bevacizumab (Avastin ) for neovascular glaucoma secondary to ischaemic central retinal vein occlusion Author: William Horsley Lead Pharmacist for April 2011 2011 Summary Neovascular glaucoma is an acutely
More informationGlaucoma Surgical Treatments. Murray Fingeret, OD Justin Schweitzer, OD Joe Sowka, OD
Glaucoma Surgical Treatments Murray Fingeret, OD Justin Schweitzer, OD Joe Sowka, OD Disclosures Murray Fingeret Consultant Bausch & Lomb, Alcon, Allergan Justin Schweitzer Allergan, Glaukos, Bausch and
More informationLong-term results of Ahmed glaucoma valve and Molteno implant in neovascular glaucoma
(2007) 21, 65 70 & 2007 Nature Publishing Group All rights reserved 0950-222X/07 $30.00 www.nature.com/eye Long-term results of valve and Molteno implant in neovascular glaucoma IS Yalvac, U Eksioglu,
More informationThese devices, when FDA approved, are covered for patients with glaucoma that is not adequately controlled with medical therapy.
Medical Policy Title: Aqueous Shunts and ARBenefits Approval: 10/26/2011 Devices for Glaucoma Effective Date: 01/01/2012 Document: ARB0168 Revision Date: Code(s): 66174, Transluminal dilation of aqueous
More informationGlaucoma Clinical Update. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012
Glaucoma Clinical Update Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012 Objectives Understand the different categories of glaucoma Recognize the symptoms and signs of open angle and angle-closure
More informationDiagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City
Diagnosis and treatment of diabetic retinopathy Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Disclosures Consulted for Novo Nordisk 2017,2018. Will be discussing
More informationLong-term Results from Cyclocryotherapy Applied to the 3 O clock and 9 O clock Positions in Blind Refractory Glaucoma Patients
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2015;29(1):47-52 http://dx.doi.org/10.3341/kjo.2015.29.1.47 Original Article Long-term Results from Cyclocryotherapy Applied to the 3 O clock and 9
More informationIntracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma
European Journal of Ophthalmology / Vol. 18 no. 2, 2008 / pp. 255-262 Intracameral vastin dramatically resolves iris neovascularization and reverses neovascular glaucoma K.V. CHLM, S.K. GUPT, S. GROVER,
More informationCHARTING THE NEW COURSE FOR MIGS
CHARTING THE NEW COURSE FOR MIGS SEE WHAT S ON THE HORIZON CyPass Micro-Stent the next wave in micro-invasive glaucoma surgery. MICRO-INVASIVE GLAUCOMA SURGERY (MIGS) OFFERS A REVOLUTIONARY APPROACH TO
More informationTHE CURRENT TREATMENT OF GLAUCOMA IS DIrected
Three-Year Follow-up of the Tube Versus Trabeculectomy Study STEVEN J. GEDDE, JOYCE C. SCHIFFMAN, WILLIAM J. FEUER, LEON W. HERNDON, JAMES D. BRANDT, AND DONALD L. BUDENZ, ON BEHALF OF THE TUBE VERSUS
More informationRetinal Vein Occlusion (RVO) Treatment pathway- Northeast England. Retinal Vein Occlusion (RVO) with Macular oedema (MO)
Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England (Royal Victoria Infirmary, Sunderland Eye Infirmary, James Cook University Hospital, Darlington Memorial Hospital, University Hospital
More informationDevelopments in Glaucoma Surgery
Developments in Glaucoma Surgery Marlene R. Moster, MD Professor of Ophthalmology Thomas Jefferson University School of Medicine Wills Eye Hospital Philadelphia, PA When is surgery indicated? Poor control
More informationChronicity. Narrow Minded. Course Outline. Acute angle closure. Subacute angle closure. Classification of Angle Closure 5/19/2014
Chronicity Narrow Minded The management of narrow angles in the optometric practice Acute Subacute Chronic Aaron McNulty, OD, FAAO Course Outline Classification of Angle Closure Evaluation of narrow angles
More informationSecondary Glaucomas. Mr Nick Strouthidis MBBS MD PhD FRCS FRCOphth FRANZCO Consultant Ophthalmologist, Glaucoma Service, Moorfields Eye Hospital
Secondary Glaucomas Mr Nick Strouthidis MBBS MD PhD FRCS FRCOphth FRANZCO Consultant Ophthalmologist, Glaucoma Service, Moorfields Eye Hospital Introduction: What is glaucoma? Glaucoma is the name given
More informationTACKLING NEOVASCULAR GLAUCOMA. Disclosure. I have no financial interests or relationships to disclose TACKLING NEOVASCULAR GLAUCOMA
TACKLING NEOVASCULAR GLAUCOMA DARBY D. MILLER, MD MPH ASSISTANT PROFESSOR CORNEA AND ANTERIOR SEGMENT SYRIL K. DORAIRAJ, MD ASSOCIATE PROFESSOR GLAUCOMA AND ANTERIOR SEGMENT MICHAEL W. STEWART, MD PROFESSOR
More informationEXP11677SK. Financial Disclosure. None to be Declared EXP11677SK
Financial Disclosure None to be Declared Presentation overview Glaucoma Surgical History Complications of trabeculectomy Express Device Specifications Surgical Steps Clinical advantages, indications and
More informationSubject Index. Canaloplasty aqueous outflow system evaluation 110, 111 complications 118, 119 historical perspective 109, 110
Subject Index Ab externo Schlemm canal surgery, see Canaloplasty, Viscocanalostomy Ab interno Schlemm canal surgery, see istent, Trabectome Adjustable sutures 14, 15 AGV glaucoma drainage implants 43,
More informationAqueous Shunts and Stents for Glaucoma. (90321) (Formerly Aqueous Shunts for Glaucoma)
Protocol Aqueous Shunts and Stents for Glaucoma (90321) (Formerly Aqueous Shunts for Glaucoma) Medical Benefit Effective Date: 01/01/13 Next Review Date: 01/14 Preauthorization* No Review Dates: 03/10,
More informationTRABECULECTOMY. Dr. Sandra M. Johnson, MD
TRABECULECTOMY Dr. Sandra M. Johnson, MD FILTRATION OPTIONS Trabeculotomy, Schlemn s canal, internal Deep Non-penetrating Sclerectomy filtering to a scleral lake, or viscocanulostomy Trabeculectomy shunting
More informationCorrespondence should be addressed to Lu Yang; jason and Yisheng Zhong;
Ophthalmology Volume 2016, Article ID 4108490, 7 pages http://dx.doi.org/10.1155/2016/4108490 Clinical Study Intravitreal Ranibizumab Injection as an Adjuvant in the Treatment of Neovascular Glaucoma Accompanied
More informationAqueous Shunts and Stents for Glaucoma
Protocol Aqueous Shunts and Stents for Glaucoma (90321) Medical Benefit Effective Date: 04/01/14 Next Review Date: 01/15 Preauthorization No Review Dates: 03/10, 03/11, 07/11, 01/12, 09/12, 01/13, 01/14
More informationNeovascular Glaucoma Associated with Cilioretinal Artery Occlusion Combined with Perfused Central Retinal Vein Occlusion
Neovascular Glaucoma Associated with Cilioretinal Artery Occlusion Combined with Perfused Central Retinal Vein Occlusion Man-Seong Seo,* Jae-Moon Woo* and Jeong-Jin Seo *Department of Ophthalmology, Chonnam
More informationCorporate Medical Policy
Corporate Medical Policy Aqueous Shunts and Devices for Glaucoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: aqueous_shunts_and_devices_for_glaucoma 3/2010 6/2017 6/2018 6/2017
More informationGlaucoma. Glaucoma. Optic Disc Cupping
Glaucoma What is Glaucoma? Bruce James A group of diseases in which damage to the optic nerve occurs as a result of intraocualar pressure being above the physiological norm for that eye Stoke Mandeville
More informationIntravitreal bevacizumab (Avastin ) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2008.03278.x Intravitreal bevacizumab (Avastin ) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up
More informationCollaboration in the care of glaucoma patients and glaucoma suspects. Barry Emara MD FRCS(C) Nico Ristorante November 29, 2012
Collaboration in the care of glaucoma patients and glaucoma suspects Barry Emara MD FRCS(C) Nico Ristorante November 29, 2012 Goals of Collaboration Patient-centred and evidence based approach Timely access
More informationNeovascular glaucoma: a retrospective review from a tertiary center in China
Liao et al. BMC Ophthalmology (2016) 16:14 DOI 10.1186/s12886-016-0190-8 RESEARCH ARTICLE Open Access Neovascular glaucoma: a retrospective review from a tertiary center in China Na Liao, Chaohong Li,
More informationRomanian Journal of Ophthalmology, Volume 59, Issue 4, October-December pp:
Romanian Journal of Ophthalmology, Volume 59, Issue 4, October-December 2015. pp:243-247 GENERAL ARTICLE Intraoperative and postoperative complications in trabeculectomy, Clinical study Barac Ramona* **,
More informationDiabetic Retinopathy
Diabetic Retinopathy Diabetes can be classified into type 1 diabetes mellitus and type 2 diabetes mellitus, formerly known as insulin-dependent diabetes mellitus, and non-insulin diabetes mellitus, respectively.
More informationClinically Significant Macular Edema (CSME)
Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2
More informationOptometric Postoperative Cataract Surgery Management
Financial Disclosures Optometric Postoperative Cataract Surgery Management David Dinh, OD Oak Cliff Eye Clinic Dallas Eye Consultants March 10, 2015 Comanagement Joint cooperation between two or more specialists
More informationEffects of Early Postoperative Intraocular Pressure after Ahmed Glaucoma Valve Implantation on Long-term Surgical Outcomes
pissn: 111-89 eissn: 9-98 Korean J Ophthalmol 18;():91-99 https://doi.org/1.1/kjo.17.1 Original Article Effects of Early Postoperative Intraocular Pressure after Ahmed Glaucoma Valve Implantation on Long-term
More informationKeywords: malignant glaucoma; pars plana vitrectomy; risk factors; complications; intraocular pressure
Article Clinical Characteristics and Outcomes of Malignant Glaucoma after Different Procedures Treated with Pars Plana Vitrectomy: A 10-Year Retrospective Study Lina Krėpštė *, Reda Žemaitienė and Arūnas
More informationChoroidal detachment following retinal detachment surgery: An analysis and a new hypothesis to minimize its occurrence in high-risk cases
European Journal of Ophthalmology / Vol. 14 no. 4, 2004 / pp. 325-329 Choroidal detachment following retinal detachment surgery: An analysis and a new hypothesis to minimize its occurrence in high-risk
More informationMEDICAL POLICY. SUBJECT: AQUEOUS DRAINAGE DEVICES (STENTS AND SHUNTS) POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community.
More informationDiabetic Retinopathy Screening Program in the Cree Region of James Bay of Quebec
RUIS McGILL VIRTUAL HEALTH AND SOCIAL SERVICES CENTRE (CvSSS) SIMPLIFYING TELEHEALTH! Diabetic Retinopathy Screening Program in the Cree Region of James Bay of Quebec Nurse and Imager Training Prepared
More informationOCULAR PHARMACOLOGY GLAUCOMA. increased intraocular pressure. normally mm Hg. when to Tx no fixed level.
OCULAR PHARMACOLOGY GLAUCOMA increased intraocular pressure normally 12 20 mm Hg. when to Tx no fixed level. literature sets ~21 mm Hg as upper limit of normal. some safe at 30 mm Hg some may have damage
More informationVision loss in elderly. Erica Weir, April 2015
Vision loss in elderly Erica Weir, April 2015 1 Burden Enter nursing homes 3 years earlier Twice the risk of falling 4x the risk of hip fracture Independent risk factor for delirium What are the leading
More informationChoroidal Detachment after Filtering Surgery. Wan-Chen Ku, MD; Yin-Hsin Lin, MD; Lan-Hsin Chuang, MD; Ko-Jen Yang, MD
Original Article 151 Choroidal Detachment after Filtering Surgery Wan-Chen Ku, MD; Yin-Hsin Lin, MD; Lan-Hsin Chuang, MD; Ko-Jen Yang, MD Results: Background: The purpose of this study is to report the
More informationEfficacy of latanoprost in management of chronic angle closure glaucoma. Kumar S 1, Malik A 2 Singh M 3, Sood S 4. Abstract
Original article Efficacy of latanoprost in management of chronic angle closure glaucoma Kumar S 1, Malik A 2 Singh M 3, Sood S 4 1 Associate Professor, 2 Assistant Professor, 4 Professor, Department of
More informationVision loss in elderly
Vision loss in elderly Erica Weir, February 2016 1 Burden Enter nursing homes 3 years earlier Twice the risk of falling 4x the risk of hip fracture Independent risk factor for delirium What are the leading
More informationPars Plana Filtration with Multiple Laser Perforation of the Uvea for Neovascular Glaucoma Following Proliferative Diabetic Retinopathy
Pars Plana Filtration with Multiple Laser Perforation of the Uvea for Neovascular Glaucoma Following Proliferative Diabetic Retinopathy Fumihiko Mabuchi,* Hideyuki Kurihara,* Nobuchika Ogino* and Shigeo
More informationMacular edema (ME) is the most common
MANAGEMENT OF RETINAL VEIN OCCLUSIONS * Peter A. Campochiaro, MD ABSTRACT Macular edema (ME) is the most common cause of reduced vision in patients with retinal vein occlusions (RVOs). The primary cause
More informationTrabeculectomy combined with cataract extraction: a follow-up study
British Journal of Ophthalmology, 1980, 64, 720-724 Trabeculectomy combined with cataract extraction: a follow-up study R. S. EDWARDS From the Birmingham and Midland Eye Hospital, Church Street, Birmingham
More informationEvolution of the Definition of Primary Open-Angle Glaucoma
OCULAR BLOOD FLOW IN GLAUCOMA MANAGEMENT AHMED HOSSAM ABDALLA PROFESSOR AND HEAD OF OPHTHALMOLOGY DEPARTEMENT ALEXANDRIA UNIVERSITY Evolution of the Definition of Primary Open-Angle Glaucoma Former definition
More informationXEN GEL STENT MIGS 4/5/2018 OMAHA AND LINCOLN EYE AND LASER INSTITUTES XEN45 GEL STENT WHY ARE WE LOOKING FOR NEW INNOVATIONS IN GLAUCOMA SURGERY?
XEN GEL STENT OMAHA AND LINCOLN EYE AND LASER INSTITUTES MARK R. YOUNG, M.D. April 7, 2018 QUESTION: Why are we looking for alternatives to current glaucoma treatment? Look at current surgical glaucoma
More informationTHE CHRONIC GLAUCOMAS
THE CHRONIC GLAUCOMAS WHAT IS GLAUCOMA? People with glaucoma have lost some of their field of all round vision. It is often the edge or periphery that is lost. That is why the condition can be missed until
More informationObservation of curative effects of Ex-PRESS and AGV implantation in the treatment of refractory glaucoma
EXPERIMENTAL AND THERAPEUTIC MEDICINE 15: 4419-4425, 2018 Observation of curative effects of Ex-PRESS and AGV implantation in the treatment of refractory glaucoma WEN BO, DONGMEI DAI and FENGXIA SUN Department
More informationDiabetic Retinopathy A Presentation for the Public
Diabetic Retinopathy A Presentation for the Public Ray M. Balyeat, MD The Eye Institute Tulsa, Oklahoma The Healthy Eye Light rays enter the eye through the cornea, pupil and lens. These light rays are
More informationMedical Treatment in Pediatric Glaucoma
Medical Treatment in Pediatric Glaucoma By Nader Bayoumi, MD Lecturer of Ophthalmology Ophthalmology Department Alexandria University Alexandria, Egypt ESG 2012 Pediatric glaucoma is a surgical disease
More informationA Patient s Guide to Diabetic Retinopathy
Diabetic Retinopathy A Patient s Guide to Diabetic Retinopathy 840 Walnut Street, Philadelphia PA 19107 www.willseye.org Diabetic Retinopathy 1. Definition Diabetic retinopathy is a complication of diabetes
More informationThe second most common causes of blindness worldwide. ( after cataract) The commonest cause of irreversible blindness in the world Estimated that 3%
The second most common causes of blindness worldwide. ( after cataract) The commonest cause of irreversible blindness in the world Estimated that 3% of our population age > 40 have glaucoma In the past:
More informationEyePACS Grading System (Part 3): Detecting Proliferative (Neovascular) Diabetic Retinopathy. George Bresnick MD MPA Jorge Cuadros OD PhD
EyePACS Grading System (Part 3): Detecting Proliferative (Neovascular) Diabetic Retinopathy George Bresnick MD MPA Jorge Cuadros OD PhD Anatomy of the eye: 3 Normal Retina Retinal Arcades Macula Optic
More informationSubconjunctival Bevacizumab as an Adjunct to Trabeculectomy in Eyes with Refractory Glaucoma: A Case Series
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2010;24(1):47-52 DOI: 10.3341/kjo.2010.24.1.47 Case Report Subconjunctival Bevacizumab as an Adjunct to Trabeculectomy in Eyes with Refractory Glaucoma:
More informationAbbreviated Drug Evaluation: Fluocinolone acetonide intravitreal implant (Retisert )
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDiabetic Retinopatathy
Diabetic Retinopatathy Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl Zeiss Meditec Arctic DX Macula Risk Advanced
More informationPost- Penetrating Keratoplasty Glaucoma
Glaucoma Post- Penetrating Keratoplasty Glaucoma MBBS Mainak Bhattacharyya MBBS, Neha Rathie MBBS, Ritu Arora MD, DNB, Parul Jain MS, FICO Guru Nanak Eye Centre, New Delhi I association between penetrating
More informationDiabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina
Diabetic Retinopathy: Managing the Extremes J. Michael Jumper, MD West Coast Retina Case 1: EC 65 y.o. HM No vision complaints Meds: Glyburide Metformin Pioglitazone Va: 20/20 OU 20/20 Case 2: HS 68 y.o.
More informationEndoscopic Cyclophotocoagulation (ECP) in the Management of Uncontrolled Glaucoma With Prior Aqueous Tube Shunt
ORIGINAL STUDY Endoscopic Cyclophotocoagulation (ECP) in the Management of Uncontrolled Glaucoma With Prior Aqueous Tube Shunt Brian Alan Francis, MD, MS,* A. Shahem Kawji, MD,w Nguyen Thao Vo, BS,z Laurie
More informationAlastair Porteous * and Laura Crawley
Porteous and Crawley BMC Ophthalmology 2018, 18(Suppl 1):219 https://doi.org/10.1186/s12886-018-0858-3 CASE REPORT Case report of secondary pigment dispersion glaucoma, recurrent uveitis and cystoid macular
More informationSilicone oil pupillary block after laser retinopexy in aphakic eyes with presumed closed peripheral iridectomy: report of three cases
Int Ophthalmol (2014) 34:913 917 DOI 10.1007/s10792-013-9862-z CASE REPORT Silicone oil pupillary block after laser retinopexy in aphakic eyes with presumed closed peripheral iridectomy: report of three
More informationNeovascular glaucoma: a review
DOI 10.1186/s40942-016-0051-x International Journal of Retina and Vitreous REVIEW Open Access Neovascular glaucoma: a review Gustavo B. Rodrigues 1*, Ricardo Y. Abe 1, Camila Zangalli 1, Savio L. Sodre
More informationDiabetic Retinopathy
Diabetic Retinopathy Diabetes mellitus is one of the leading causes of irreversible blindness worldwide. In the United States, it is the most common cause of blindness in people younger than 65 years.
More informationContents Optic Nerve: The Glaucomatous Optic Nerve Optic Nerve: Clinical Examination Optic Nerve: Heidelberg Retinal Tomography
Contents 1 Optic Nerve: The Glaucomatous Optic Nerve................... 1 1.1 Why Is the Optic Nerve Important in the Diagnosis and Management of Glaucoma?............................ 1 References.................................................
More informationCLINICAL SCIENCES. Angiographic Changes in Iris and Iridocorneal Angle Neovascularization After Intravitreal Bevacizumab Injection
LINIAL SIENES Angiographic hanges in Iris and Iridocorneal Angle Neovascularization After Intravitreal evacizumab Injection Shingo Ishibashi, M; Akihiko Tawara, M; Rika Sohma, M; Toshiaki Kubota, M; Norihiko
More informationDiabetic retinopathy (DR) progressively
FOCUS ON DIABETIC MACULAR EDEMA * Frederick L. Ferris III, MD ABSTRACT The current state of treatment for diabetic macular edema (DME) is focused on slowing the rate of vision loss through assessment of
More informationCLINICAL SCIENCES. Complications of Baerveldt Glaucoma Drainage Implants. such as the Baerveldt implant are used in the surgical
CLINICAL SCIENCES Complications of Baerveldt Glaucoma Drainage Implants Quang H. Nguyen, MD; Donald L. Budenz, MD; Richard K. Parrish II, MD Objectives: To report the incidence and identify risk factors
More informationNeovascular glaucoma after central retinal vein occlusion in pre-existing glaucoma
Chen et al. BMC Ophthalmology 2014, 14:119 RESEARCH ARTICLE Open Access Neovascular glaucoma after central retinal vein occlusion in pre-existing glaucoma Hsi-Fu Chen 1, Min-Chi Chen 3,4, Chi-Chun Lai
More information